Abbisko Cayman (HKG:2256) recorded a profit of 28.3 million yuan for the year 2024, compared with a loss of 431.6 million yuan in the year-ago period, a Monday filing with the Hong Kong bourse stated.
Earnings per share were 0.04 yuan in the year, while the company had incurred a loss per share of 0.67 yuan in the corresponding period last year.
The drugmaker's revenue rose by 2,544% year over year to 504 million yuan from 19.1 million yuan a year prior.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。